Higher doses of a Viking Therapeutics pill that targets two receptors led to greater weight loss without worsening safety or tolerability, according to Phase 1 results presented during the ObesityWeek conference. Meanwhile, an injectable version of this Viking drug is on track to Phase 3 testing.
The post Viking Therapeutics’ Early Clinical Data Continue to Build Case for Its Oral Obesity Drug appeared first on MedCity News.
